Gastrointestinal Cancer Archives - MPR

Gastrointestinal Cancer

MPR Weekly Dose Podcast Episode 26

This week we talk about a phase 1 trial for a potential COVID-19 vaccine that is underway in Seattle; Concerns over COVID-19 and ACE inhibitor, ARB use; Safety labeling changes for SGLT2 inhibitors; A biosimilar to Herceptin; And new graphic warnings for cigarette packages.

Ayvakit Approval for GI Stromal Tumor With PDGFRA Mutation

The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

Mylan Launches Generic Xeloda

Ogivri, a Biosimilar to Herceptin, Now Available in the US

Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab; Genentech) has been made available by Mylan and Biocon Biologics. Ogivri, a HER2/neu receptor antagonist, is indicated for: Adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with 1 high risk feature) breast cancer as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and…